May 10, 2022
Medical Funding Professionals (MFP) is pleased to announce that HealthySole has engaged MFP to implement the Capital Planning Valuation Strategy™ Co-Chaired by Scott Pantel of LSI and Stephen Brock of MFP in preparation of the company’s Regulation A+ offering.
HealthySole is a commercial-stage Medtech company and developer of HealthySole® PLUS – the first independently validated shoe sanitizer designed to prevent pathogen contamination and transmission. Current practices for curbing and preventing the spread of pathogen transmission on shoes and floors do not adequately address the needs of medical care facilities aiming to minimize healthcare-acquired infections as well as exposure to healthcare providers. The HealthySole® PLUS shoe sanitizer is clinically proven to kill up to 99.99% of infections, contaminations, and pathogens in only 8 seconds, offering a revolutionary solution for medical care facilities.
“This technology is a game-changer for the infection prevention market,” says HealthySole Founder and CEO Peter Kassel. “Many common disinfectants use toxic chemicals harmful to clothing and skin. Our sanitizer adds nothing to the shoe; it uses UV light in a controlled dose and automatically runs a complete treatment.”
Hospitals and surgery centers are constantly improving IPC protocols to reduce infection risk, particularly within the context of today’s Covid-19 environment. HealthySole’s market, however, is not limited to medical care facilities: compounding labs, long-term living facilities, first responders, and municipalities are among several additional verticals with uses for sterilization technology.
“There is a tremendous opportunity to extend into other use areas outside of hospitals,” continues Kassel. “When you think of all the places that need to frequently disinfect clothing to maintain a sterile environment – food processing, fire stations, law enforcement – you realize just how big this can get.”
HealthySole’s plan now is to expand distribution in new and existing verticals while increasing product awareness in its core markets. The company has signed a deal with a leading medical supply distributor, however the cost of elevating the brand on a national scale will not come cheap. “We needed a strategic plan for capital that will help us expand our reach as we deepen penetration in hospitals and medical care units,” says Kassel. “That’s what Medical Funding Professionals has outlined for us, and we look forward to working with them to help us reach our next milestones.”
“We’re delighted to be working with HealthySole,” says Medical Funding Professionals CEO Stephen Brock. “HealthySole has identified an unmet need in the healthcare disinfection market and the potential for this technology is massive. We’ll do whatever it takes to bring this technology to market while keeping founders in control of the company they worked so hard to build.”
“This is what excites me most about the medtech industry,” says Scott Pantel, CEO of medtech market research firm Life Science Intelligence, an MFP strategic partner. “HealthySole has developed a truly groundbreaking technology that will improve sanitation practices not just in hospitals but in a variety of environments. We see it as our mission to guide HealthySole through the capital raising process and to assist them on the next stage of their journey.”
HealthySole will be among 100 vetted presenting companies attending the LSI Europe ’22 Emerging Medtech Summit in London taking place on September 21-24, 2022. In addition to company presentations, the event will feature panel sessions with investors, one-on-one meetings, and vast networking opportunities with leading medtech investors, strategics, and industry insiders.
HealthySole is a medical equipment manufacturer and developer of HealthySole® PLUS – the first independently validated shoe sanitizer designed to prevent pathogen contamination and transmission. The HealthySole® PLUS shoe sanitizer uses germicidal UV light to eliminate shoe-borne pathogens, decrease ambient contamination, and reduce the risk of contamination-causing bacteria in the workplace. The HealthySole® PLUS shoe sanitizer has been tested and clinically proven to kill up to 99.99% of pathogens in only 8 seconds, offering a groundbreaking sterilization solution to customers in the medical care, clean room, law enforcement, food processing, and hospitality sectors.
HealthySole is considering an offering of securities exempt from registration under the Securities Act of 1933, but has not determined a specific exemption from registration it intends to rely on for the subsequent offer and sale of the securities. No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until HealthySole determines the exemption under which the offering is intended to be conducted and, where applicable, the filing, disclosure, or qualification requirements of such exemption are met. A person's indication of interest involves no obligation or commitment of any kind.
About Medical Funding Professionals
Medical Funding Professionals is a registered investment advisor firm providing capital and cash flow planning solutions to the medical industry, including life sciences, biotech, medtech, and pharmaceutical sectors. Their Capital Planning Valuation Strategy™ (CPVS) ensures founders and key executives maintain control of their companies as they raise capital and grow. Medical Funding Professionals compliments its advisory services by providing further guidance on how to utilize the updated private company exemptions such as 506c for accredited investors and Reg A+ which allows a company to raise up to $75M from both accredited and non-accredited every 12 months.
About Life Science Intelligence
LSI is a medical technology-focused market intelligence & consulting company that helps medtech executives make informed strategic decisions by better understanding market dynamics, trends, opportunities and the competitive landscape.
Regulation A+ Disclaimer
This communication may be deemed to be a solicitation of interest under Regulation A under the Securities Act of 1933, in which case the following apply: